<?xml version='1.0' encoding='utf-8'?>
<document id="19385713"><sentence text="Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma."><entity charOffset="45-55" id="DDI-PubMed.19385713.s1.e0" text="omeprazole" /><entity charOffset="102-112" id="DDI-PubMed.19385713.s1.e1" text="bortezomib" /><pair ddi="false" e1="DDI-PubMed.19385713.s1.e0" e2="DDI-PubMed.19385713.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19385713.s1.e0" e2="DDI-PubMed.19385713.s1.e1" /></sentence><sentence text="Bortezomib, an antineoplastic for the treatment of relapsed multiple myeloma and mantle cell lymphoma, undergoes metabolism through oxidative deboronation by cytochrome P450 (CYP) enzymes, primarily CYP3A4 and CYP2C19"><entity charOffset="0-10" id="DDI-PubMed.19385713.s2.e0" text="Bortezomib" /></sentence><sentence text=" Omeprazole, a proton-pump inhibitor, is primarily metabolized by and demonstrates high affinity for CYP2C19"><entity charOffset="1-11" id="DDI-PubMed.19385713.s3.e0" text="Omeprazole" /></sentence><sentence text=" This study investigated whether coadministration of omeprazole affected the pharmacokinetics, pharmacodynamics and safety profile of bortezomib in patients with advanced cancer"><entity charOffset="53-63" id="DDI-PubMed.19385713.s4.e0" text="omeprazole" /><entity charOffset="134-144" id="DDI-PubMed.19385713.s4.e1" text="bortezomib" /><pair ddi="false" e1="DDI-PubMed.19385713.s4.e0" e2="DDI-PubMed.19385713.s4.e0" /><pair ddi="false" e1="DDI-PubMed.19385713.s4.e0" e2="DDI-PubMed.19385713.s4.e1" /></sentence><sentence text=" The variability of bortezomib pharmacokinetics with CYP enzyme polymorphism was also investigated"><entity charOffset="20-30" id="DDI-PubMed.19385713.s5.e0" text="bortezomib" /></sentence><sentence text="" /><sentence text="This open-label, crossover, pharmacokinetic drug-drug interaction study was conducted at seven institutions in the US and Europe between January 2005 and August 2006" /><sentence text=" Patients who had advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma, were aged &gt;/=18 years, weighed &gt;/=50 kg and had a life expectancy of &gt;/=3 months were eligible" /><sentence text=" Patients received bortezomib 1"><entity charOffset="19-29" id="DDI-PubMed.19385713.s9.e0" text="bortezomib" /></sentence><sentence text="3 mg/m2 on days 1, 4, 8 and 11 for two 21-day cycles, plus omeprazole 40 mg in the morning of days 6-10 and in the evening of day 8 in either cycle 1 (sequence 1) or cycle 2 (sequence 2)"><entity charOffset="59-69" id="DDI-PubMed.19385713.s10.e0" text="omeprazole" /></sentence><sentence text=" On day 21 of cycle 2, patients benefiting from therapy could continue to receive bortezomib for six additional cycles"><entity charOffset="82-92" id="DDI-PubMed.19385713.s11.e0" text="bortezomib" /></sentence><sentence text=" Blood samples for pharmacokinetic/pharmacodynamic evaluation were collected prior to and at various timepoints after bortezomib administration on day 8 of cycles 1 and 2"><entity charOffset="118-128" id="DDI-PubMed.19385713.s12.e0" text="bortezomib" /></sentence><sentence text=" Blood samples for pharmacogenomics were also collected" /><sentence text=" Pharmacokinetic parameters were calculated by noncompartmental analysis of plasma concentration-time data for bortezomib administration on day 8 of cycles 1 and 2, using WinNonlin version 4"><entity charOffset="111-121" id="DDI-PubMed.19385713.s14.e0" text="bortezomib" /></sentence><sentence text="0" /><sentence text="1" /><sentence text="a software" /><sentence text=" The pharmacodynamic profile was assessed using a whole-blood 20S proteasome inhibition assay" /><sentence text="" /><sentence text="Twenty-seven patients (median age 64 years) were enrolled, 12 in sequence 1 and 15 in sequence 2, including eight and nine pharmacokinetic-evaluable patients, respectively" /><sentence text=" Bortezomib pharmacokinetic parameters were similar when bortezomib was administered alone or with omeprazole (maximum plasma concentration 120 vs 123 ng/mL; area under the plasma concentration-time curve from 0 to 72 hours 129 vs 135 ng "><entity charOffset="1-11" id="DDI-PubMed.19385713.s21.e0" text="Bortezomib" /><entity charOffset="57-67" id="DDI-PubMed.19385713.s21.e1" text="bortezomib" /><entity charOffset="99-109" id="DDI-PubMed.19385713.s21.e2" text="omeprazole" /><pair ddi="false" e1="DDI-PubMed.19385713.s21.e0" e2="DDI-PubMed.19385713.s21.e0" /><pair ddi="false" e1="DDI-PubMed.19385713.s21.e0" e2="DDI-PubMed.19385713.s21.e1" /><pair ddi="false" e1="DDI-PubMed.19385713.s21.e0" e2="DDI-PubMed.19385713.s21.e2" /><pair ddi="false" e1="DDI-PubMed.19385713.s21.e1" e2="DDI-PubMed.19385713.s21.e1" /><pair ddi="false" e1="DDI-PubMed.19385713.s21.e1" e2="DDI-PubMed.19385713.s21.e2" /></sentence><sentence text=" h/mL)" /><sentence text=" The pharmacodynamic parameters were also similar (maximum effect 85" /><sentence text="8% vs 93" /><sentence text="7%; area under the percent inhibition-time curve over 72 hours 4052 vs 3910 % x h); the differences were not statistically significant" /><sentence text=" Pharmacogenomic analysis revealed no meaningful relationships between CYP enzyme polymorphisms and pharmacokinetic/pharmacodynamic parameters" /><sentence text=" Toxicities were generally similar between patients in sequence 1 and sequence 2, and between cycle 1 and cycle 2 in both treatment sequences" /><sentence text=" Among 26 evaluable patients, 13 (50%) were assessed as benefiting from bortezomib at the end of cycle 2 and continued to receive treatment"><entity charOffset="72-82" id="DDI-PubMed.19385713.s28.e0" text="bortezomib" /></sentence><sentence text="" /><sentence text="No impact on the pharmacokinetics, pharmacodynamics and safety profile of bortezomib was seen with coadministration of omeprazole"><entity charOffset="74-84" id="DDI-PubMed.19385713.s30.e0" text="bortezomib" /><entity charOffset="119-129" id="DDI-PubMed.19385713.s30.e1" text="omeprazole" /><pair ddi="false" e1="DDI-PubMed.19385713.s30.e0" e2="DDI-PubMed.19385713.s30.e0" /><pair ddi="false" e1="DDI-PubMed.19385713.s30.e0" e2="DDI-PubMed.19385713.s30.e1" /></sentence><sentence text=" Concomitant administration of bortezomib and omeprazole is unlikely to cause clinically significant drug-drug interactions and is unlikely to have an impact on the efficacy or safety of bortezomib"><entity charOffset="31-41" id="DDI-PubMed.19385713.s31.e0" text="bortezomib" /><entity charOffset="46-56" id="DDI-PubMed.19385713.s31.e1" text="omeprazole" /><entity charOffset="187-197" id="DDI-PubMed.19385713.s31.e2" text="bortezomib" /><pair ddi="false" e1="DDI-PubMed.19385713.s31.e0" e2="DDI-PubMed.19385713.s31.e0" /><pair ddi="false" e1="DDI-PubMed.19385713.s31.e0" e2="DDI-PubMed.19385713.s31.e1" /><pair ddi="false" e1="DDI-PubMed.19385713.s31.e0" e2="DDI-PubMed.19385713.s31.e2" /><pair ddi="false" e1="DDI-PubMed.19385713.s31.e1" e2="DDI-PubMed.19385713.s31.e1" /><pair ddi="false" e1="DDI-PubMed.19385713.s31.e1" e2="DDI-PubMed.19385713.s31.e2" /></sentence><sentence text="" /></document>